Chi H. Leung

Liyang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Impact of different treatment modalities for localized prostate cancer on patient-reported quality of life outcomes in an Asian Cohort.

Impact of different treatment modalities for localized prostate cancer on patient-reported quality of life outcomes in an Asian Cohort.

Journal: Scientific reports

Published: February 23, 2026

Disease characteries, treatment patterns, and oncological outcomes of de novo metastatic hormone-sensitive prostate cancer: real-world experience from a multicenter Asian cohort.

Disease characteries, treatment patterns, and oncological outcomes of de novo metastatic hormone-sensitive prostate cancer: real-world experience from a multicenter Asian cohort.

Journal: Asian journal of andrology

Published: September 09, 2025

Suction mini-percutaneous nephrolithotomy versus standard percutaneous nephrolithotomy for the management of 2-4 cm kidney stones: study protocol for an international, multicenter, parallel-group, noninferiority, randomized controlled trial.

Suction mini-percutaneous nephrolithotomy versus standard percutaneous nephrolithotomy for the management of 2-4 cm kidney stones: study protocol for an international, multicenter, parallel-group, noninferiority, randomized controlled trial.

Journal: World journal of urology

Published: August 31, 2025

A cross-sectional study on the effects of intravesical BCG on urinary microbiota in bladder cancer patients.

A cross-sectional study on the effects of intravesical BCG on urinary microbiota in bladder cancer patients.

Journal: International urology and nephrology

Published: February 10, 2025

Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients.

Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients.

Journal: Prostate cancer and prostatic diseases

Published: February 08, 2025

Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer.

Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer.

Journal: Cancer

Published: April 30, 2024

Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study.

Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study.

Journal: Prostate cancer and prostatic diseases

Published: January 27, 2024

Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study.

Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study.

Journal: Prostate cancer and prostatic diseases

Published: June 08, 2023

Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population-based cohort study.

Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population-based cohort study.

Journal: Cancer medicine

Published: March 27, 2023

A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.

A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.

Journal: European urology

Published: June 25, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026